The number of infections caused by the antibiotic-resistant bacterium Klebsiella pneumoniae is rising in European hospitals. Politico reported this on November 18, citing a report by the European Centre for Disease Prevention and Control (ECDC).
“A dangerous drug-resistant superbug is gaining ground in European hospitals, spreading between patients and becoming increasingly difficult to treat,” the newspaper reported.
According to the ECDC report, the number of bloodstream infections caused by treatment-resistant Klebsiella pneumoniae increased by 72% between 2019 and 2025. This figure is far off the European Union's target of reducing such infections by 5% by 2030.
The agency noted that some strains of the bacterium are developing resistance to virtually all available antibiotics, including new drugs. This complicates treatment and increases the risk of severe complications. The infection poses a particular threat to hospital patients because the bacterium can spread between them.
ECDC representative Christian Giske described the situation involving treatment-resistant Klebsiella pneumoniae as the leading concern in the past year's data on the spread of superbugs in Europe. He said healthcare facilities need to strengthen preventive measures to contain the infection, including hand hygiene, the use of personal protective equipment and regular disinfection of premises.
Meanwhile, experts highlighted differences in the spread of other antibiotic-resistant bacteria. The number of bloodstream infections caused by MRSA in 2025 was 19% lower than in 2019. This exceeded the EU's target of reducing such cases by 15% by 2030. At the same time, the number of infections caused by drug-resistant E. coli increased by 16.4% over the same period.
The agency's director, Pamela Rendi-Wagner, stressed that genomic surveillance must be improved to combat the spread of resistant bacteria. It enables faster tracking of infection transmission routes, timely detection of threats and identification of the most effective treatments.










